In recent years, precision treatment for lung cancer has continued to advance, and EGFR-mutant non-small cell lung cancer (NSCLC) has entered the era of targeted therapy. In particular, the emergence of third-generation EGFR-TKI drugs has enabled more patients to achieve longer survival and better quality of life. However, drug resistance remains an unavoidable core challenge in the treatment of EGFR-mutant lung cancer.

Today, a new treatment strategy is attracting widespread attention in the industry: the oral PD-L1 small-molecule inhibitor ABSK043 combined with Furmonertinib, offering a completely oral, chemotherapy-free treatment approach for patients with EGFR-mutant, PD-L1-positive advanced lung cancer. This may not only reshape the traditional treatment landscape of EGFR-mutant lung cancer, but also signal that the combination of targeted therapy and immunotherapy is entering a new stage.

---

Why Does EGFR-Mutant Lung Cancer Still Face Treatment Challenges?

EGFR mutations are among the most common driver gene mutations in Asian patients with non-small cell lung cancer. Studies show that the EGFR mutation rate in Asian lung adenocarcinoma patients can reach 40%–50%.

Therefore, EGFR-TKIs have become an important standard treatment option for this patient population.

Common third-generation EGFR-TKIs currently include:

• Osimertinib
• Furmonertinib

Among them, Furmonertinib has received widespread attention in China’s EGFR lung cancer treatment field in recent years.

Compared with earlier EGFR-TKIs:

• Third-generation drugs have stronger control over brain metastases
• Relatively lower adverse reactions
• Significantly prolonged progression-free survival

Even so, most patients still gradually develop resistance within 1–2 years.

After resistance occurs, treatment often faces:

• Limited subsequent treatment options
• Greater chemotherapy-related side effects
• A more complex tumor microenvironment
• Increased difficulty in disease control

Therefore, how to delay resistance and further extend disease control time has become an important research direction in EGFR lung cancer treatment.

---

Why Has Immunotherapy Long Been Less Beneficial for EGFR-Mutant Patients?

Over the past few years, PD-1/PD-L1 immunotherapy has completely changed the treatment landscape of advanced non-small cell lung cancer.

Including:

• Pembrolizumab
• Sintilimab
• Durvalumab

These PD-(L)1 antibody drugs have achieved breakthrough progress across multiple cancer types.

However, EGFR-mutant patients have long been considered a special population with relatively low benefit from immunotherapy.

The main reasons include:

• EGFR-mutant tumors have lower immunogenicity
• The tumor microenvironment is relatively “cold”
• Insufficient T-cell infiltration
• Limited efficacy of PD-1/PD-L1 monotherapy

Some studies have even found that certain EGFR-mutant patients receiving immunotherapy alone may experience:

• Hyperprogression
• Severe immune-related pneumonitis
• Increased treatment-related toxicity

Therefore, for a long time, EGFR-mutant lung cancer patients have not been the primary beneficiaries of immunotherapy.

---

Targeted Therapy Combined with Immunotherapy: A New Breakthrough Direction

However, in recent years, more and more studies have found that EGFR-TKIs and PD-L1 inhibitors may have synergistic mechanisms.

The core logic includes:

1️⃣ EGFR-TKIs May Increase Tumor Antigen Release

Targeted drugs can induce tumor cell death, thereby releasing more tumor antigens and enhancing immune system recognition.

2️⃣ Combination Immunotherapy May Improve the Tumor Microenvironment

PD-L1 inhibitors can reactivate T cells and enhance the immune system’s sustained attack on tumors.

3️⃣ Potential to Delay Drug Resistance

Some studies suggest that combination therapy may help prolong disease control time achieved by EGFR-TKIs.

Especially for PD-L1-positive EGFR-mutant patients, combination regimens may provide greater clinical benefit.

It is against this background that research on ABSK043 combined with Furmonertinib has gradually gained attention.

---

ABSK043: Why Is This Oral PD-L1 Inhibitor Unique?

Currently, mainstream clinical PD-1/PD-L1 drugs are mostly monoclonal antibodies.

Although these drugs have proven efficacy, they usually require:

• Intravenous infusion
• Long-term hospital administration
• Outpatient infusion management

ABSK043, however, is an oral small-molecule PD-L1 inhibitor.

This is also one of the important innovative directions in the global immunotherapy field today.

Its core characteristics include:

• Oral administration
• Small-molecule structure
• More flexible combination therapy
• Avoidance of infusion-related reactions
• No anti-drug antibody issues

Compared with traditional antibody-based immunotherapy drugs, oral PD-L1 inhibitors are expected to significantly improve patient convenience.

---

What Does the “Dual Oral” Model Mean?

One of the biggest features of ABSK043 combined with Furmonertinib is:

“Dual oral therapy, chemotherapy-free.”

Traditional combination treatment for advanced lung cancer usually requires:

• Intravenous infusion
• Long hospital stays
• Management of chemotherapy-related side effects

In contrast, a dual oral regimen may bring:

• More convenient long-term treatment
• Improved patient adherence
• Reduced pressure on outpatient infusion services
• Lower chemotherapy-related toxicity
• Improved quality of life

Especially for elderly patients, frail patients, patients requiring long-term maintenance therapy, and those unwilling to undergo chemotherapy, the dual oral model has strong appeal.

As lung cancer increasingly becomes a chronic disease requiring long-term management, treatment convenience is becoming a new area of competition.

---

Why Has Furmonertinib Become the Core of Combination Therapy?

Furmonertinib is one of China’s independently developed third-generation EGFR-TKIs.

In recent years, its application in EGFR-mutant advanced NSCLC has continued to expand.

Compared with some earlier EGFR-TKIs, Furmonertinib offers:

• Good central nervous system penetration
• More stable blood drug concentrations
• Better suitability for patients with brain metastases
• Relatively favorable safety profile

Therefore, Furmonertinib has also become one of the important backbone drugs in current EGFR combination therapy research.

---

Conclusion

For patients with EGFR-mutant non-small cell lung cancer, drug resistance remains the core challenge during long-term treatment.

The emergence of ABSK043 combined with Furmonertinib has brought a new treatment concept for patients with EGFR-mutant, PD-L1-positive advanced lung cancer.

As a new model featuring dual oral administration, chemotherapy-free treatment, and the combination of targeted therapy with immunotherapy, its future development deserves continued attention.

As more clinical research data are released, EGFR lung cancer treatment may truly be entering a “chemotherapy-free era.”

DengYueMed continues to monitor the latest global advances in oncology treatment and provides timely updates on emerging research developments and innovative therapies.